DMK Pharmaceuticals Corp
OTC:DMKPQ

Watchlist Manager
DMK Pharmaceuticals Corp Logo
DMK Pharmaceuticals Corp
OTC:DMKPQ
Watchlist
Price: 0.0001 USD Market Closed
Market Cap: $10

Relative Value

There is not enough data to reliably calculate the relative value of DMKPQ.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

DMKPQ Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

DMKPQ Competitors Multiples
DMK Pharmaceuticals Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
DMK Pharmaceuticals Corp
OTC:DMKPQ
10 USD 0 -0 0.3 0.3
US
Eli Lilly and Co
NYSE:LLY
1T USD 17 54.8 36.8 39.4
UK
Dechra Pharmaceuticals PLC
F:1PK
5.1B EUR 6.8 -184.5 42.7 196.5
US
Johnson & Johnson
NYSE:JNJ
528.7B USD 5.6 19.7 13.8 16.9
CH
Roche Holding AG
SIX:ROG
275.3B CHF 4.5 29.2 12.4 14.5
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP 4.9 30.2 19.7 28.8
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 5.6 17.2 11.9 13.9
CH
Novartis AG
SIX:NOVN
221.9B CHF 5 19.5 15.7 20.2
US
Merck & Co Inc
NYSE:MRK
267.9B USD 4.2 14.1 10 11.8
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
145.6B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
US
DMK Pharmaceuticals Corp
OTC:DMKPQ
Average P/E: 24.9
Not Available
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.8
54%
1
UK
D
Dechra Pharmaceuticals PLC
F:1PK
Negative Multiple: -184.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.7
6%
3.3
CH
Roche Holding AG
SIX:ROG
29.2
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.2
38%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
17.2
2%
8.6
CH
Novartis AG
SIX:NOVN
19.5
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.1
14%
1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
DMK Pharmaceuticals Corp
OTC:DMKPQ
Average EV/EBITDA: 46.9
0.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.8
34%
1.1
UK
D
Dechra Pharmaceuticals PLC
F:1PK
42.7
36%
1.2
US
Johnson & Johnson
NYSE:JNJ
13.8
2%
6.9
CH
Roche Holding AG
SIX:ROG
12.4
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
19.7
10%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.9
1%
11.9
CH
Novartis AG
SIX:NOVN
15.7
6%
2.6
US
Merck & Co Inc
NYSE:MRK
10
6%
1.7
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
DMK Pharmaceuticals Corp
OTC:DMKPQ
Average EV/EBIT: 110.7
0.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.4
37%
1.1
UK
D
Dechra Pharmaceuticals PLC
F:1PK
196.5
98%
2
US
Johnson & Johnson
NYSE:JNJ
16.9
6%
2.8
CH
Roche Holding AG
SIX:ROG
14.5
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
28.8
23%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.9
0%
N/A
CH
Novartis AG
SIX:NOVN
20.2
12%
1.7
US
Merck & Co Inc
NYSE:MRK
11.8
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5